Table 1.
Baseline Characteristics
| n/N | Overall | Dead | Alive | p-value | |
|---|---|---|---|---|---|
| % | n=104 | n=46 | n=58 | ||
| Age (years) median (range) | 100 | 49.5 (62) | 49 (58) | 50 (62) | 0.7 |
| Gender (male) [n (%)] | 100 | 61 (58.7) | 29 (63) | 32 (55.2) | 0.3 |
| ECOG/WHO performance status (grade1/2/3/4) (n) | 90 | 11/43/39/1 | 4/19/16/1 | 7/24/23/0 | 0.6 |
| Ascites (yes) n (%) | 100 | 73 (70.2) | 35 (76) | 38 (65.5) | 0.2 |
| Encephalopathy (yes) grade 1/grade 2/grade 3 (n) | 95 | 80/7/12 | 37/5/2 | 43/2/10 | 0.052 |
| Size of the liver (cm) median (range) | 67.3 | 15.4 (13) | 15.5 (13) | 15.2 (11) | 0.7 |
| Number of nodules ≥ 3 [n (%)] | 96 | 73 (70) | 32 (69,6) | 41 (76) | 0.2 |
| Nodule localization (segmental/lobular/diffuse) (n) | 91 | 48/18/29 | 19/9/15 | 29/9/14 | 0.5 |
| Nodule size (cm) median (range) | 40.4 | 5.5 (14.4) | 5.0 (14.4) | 6.1 (12) | 0.9 |
| Portal vein thrombosis (yes) n (%) | 94 | 23 (23.5) | 8 (17.4) | 15 (25.9) | 0.3 |
| Lung, node or peritoneal metastasis (n) | 98 | 9/14 /4 | 7/9/2 | 2/5/2 | – |
| Alpha-fetoprotein level (ng/mL) median (range) | 63.5 | 1084 (933,469) | 136 (80,000) | 6122 (933,469) | 0.001 |
| Hemoglobin (g/dL) median (range) | 93.3 | 9 (13) | 9.5 (10) | 8.3 (11) | 0.3 |
| Lymphocytes (cells/mL) median (range) | 88.5 | 1881 (9390) | 1820 (5390) | 1960 (9264) | 0.3 |
| Platelet count (103cel/mL) median (range) | 98.1 | 168 (522) | 191 (522) | 164 (442) | 0.2 |
| PMN (cells/mL) median (range) | 88.5 | 4153 (22,710) | 4506 (22,520) | 3897 (18,610) | 0.4 |
| Prothrombin time (%) median (range) | 90.4 | 70 (81) | 63 (81) | 72 (70) | 0.07 |
| Albumin (mg/L) median (range) | 97.1 | 29 (28) | 26 (25) | 31 (24) | 0.02 |
| INR median (range) | 77.9 | 1.3 (3.8) | 1.4 (3.8) | 1.3 (1.8) | 0.2 |
| Bilirubin (mg/dL) median (range) | 98.1 | 2.5 (28.2) | 3.2 (25) | 2.5 (28) | 0.5 |
| Creatinine (mg/dL) median (range) | 90.4 | 1.0 (2.5) | 1.0 (2.5) | 0.9 (2.2) | 0.2 |
| ALT (IU/L) median (range) | 87.5 | 72 (1733) | 84 (1731) | 68 (215) | 0.1 |
| CTP score median (range)] | 100 | 8 (7) | 9 (7) | 8 (6) | 0.01 |
| CTP in class (class A/class B/class C) (n) | 100 | 14/63/27 | 9/39/10 | 5/24/17 | 0.07 |
| BCLC stages (B/C/D) (n) | 100 | 41 /30 /33 | 15/13/18 | 26/17/15 | 0.3 |
| MELD score median (range) | 69.2 | 14.5 (36) | 15.4 (35.9) | 13.9 (22.9) | 0.2 |
| MELD score >16.5 n (%) | 69.2 | 24 (33.3) | 14 (42.4). | 10 (25.6) | 0.1 |
| NLR median (range) | 78.8 | 2.4 (17) | 3.1 (16) | 2.1 (17) | 0.1 |
| NLR >2.5 n (%) | 78.8 | 39 (47.6) | 23 (59) | 16 (37.2) | 0.05 |
| PLR median (range)] | 78.8 | 89.2 (512.5) | 108.4 (513) | 80.5 (322) | 0.07 |
| PLR >92 n(%) | 78.8 | 40 (48.8) | 22 (56.4) | 14 (32.6) | 0.05 |
| Length of stay (days) median (range) | 100 | 8 (79) | 7 (61) | 8 (79) | 0.6 |
| Mortality rate at 30 days n(%) | 100 | 43(41.3) | – | – | – |
Note: All values are rounded to the next integer if necessary.
Abbreviations: n/N, percentage of complete data, The range equals maximum value minus minimum value; PMN, polymorphonuclear cell; INR, international normalized ratio; ALT, alanine amino transferase; CTP, Child–Turcotte–Pugh; BCLC, Barcelona clinic liver cancer; MELD, model for end-stage liver disease; NLR, neutrophil-to-lymphocyte ratio; PLR, platelet-to-lymphocyte ratio.